Similarity of biotechnology-derived medicinal products: specific problems and new regulatory framework.
about
Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.Minimising harm: human variation and adverse drug reactions (ADRs)Managing unexpected events in the manufacturing of biologic medicines.Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
P2860
Similarity of biotechnology-derived medicinal products: specific problems and new regulatory framework.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Similarity of biotechnology-de ...... and new regulatory framework.
@en
Similarity of biotechnology-de ...... and new regulatory framework.
@nl
type
label
Similarity of biotechnology-de ...... and new regulatory framework.
@en
Similarity of biotechnology-de ...... and new regulatory framework.
@nl
prefLabel
Similarity of biotechnology-de ...... and new regulatory framework.
@en
Similarity of biotechnology-de ...... and new regulatory framework.
@nl
P1476
Similarity of biotechnology-de ...... and new regulatory framework.
@en
P2093
Jean-Louis Prugnaud
P304
P356
10.1111/J.1365-2125.2007.03062.X
P407
P577
2007-12-17T00:00:00Z